He Woke Up Blind. His Doctor Never Mentioned Ozempic Could Do This.
He drove snowplows for a living.
Sixty-two years old. Howard County, Maryland. Motor equipment operator for the county government. The kind of man who shows up before dawn because a road needs clearing and he is the person who clears it.
His doctor gave him Ozempic in August 2023. Type 2 diabetes. The drug was everywhere by then. Morning news. Celebrity gossip. Pharmacy waiting rooms. The most talked-about medication in America, maybe ever.
He woke up and could not see out of his right eye.
Not blurry. Not dim. Gone. Just gone.
The doctors gave it a name: non-arteritic anterior ischemic optic neuropathy. NAION. An eye stroke, basically. Blood stops flowing to the optic nerve. The nerve tissue dies. The vision does not come back. No surgery fixes it. No medication reverses it. You wake up with one working eye and that is simply what your life is now.
Nobody told him Ozempic could do this. Nothing on the box. Nothing from the pharmacist. Nothing from the doctor who wrote the prescription.
Ten months later, October 2024, he woke up and could not see out of his left eye either.
His name is Todd Engel. He is legally blind. He had to resign from his job. He cannot drive. He sat through his grandson's bar mitzvah and listened to something he could not see.
He told a reporter: "I want the manufacturers of Ozempic to see me. That I cannot see anything. I'm blind. I'm legally blind, and this is devastating."
Here is the part that makes this story something more than one man's tragedy.
Late summer 2023. A few months before Engel lost his first eye. Boston, Massachusetts. Mass Eye and Ear, one of the best neuro-ophthalmology programs in the world, affiliated with Harvard Medical School.
A senior doctor named Joseph Rizzo was reviewing the week's patient intake with his trainees. Rizzo is the director of the Neuro-Ophthalmology Service there, a Harvard professor, someone who has spent decades looking at rare optic nerve conditions.
He had seen three new NAION cases in seven days.
All three were on semaglutide. The active drug inside Ozempic.
NAION is uncommon. Roughly 2.3 to 10.2 cases per 100,000 adults over age fifty, per year. Three cases in one week at one clinic is the kind of clustering that experienced clinicians notice and do not let go of. His fellow, Tatiana Hathaway, started pulling charts. They went back through six years of patient records. Sixteen thousand, eight hundred and twenty-seven patients total. They built a matched cohort and ran the statistics.
The results were not subtle.
Diabetic patients on semaglutide were 4.28 times more likely to develop NAION than diabetic patients on other medications. Obese patients on semaglutide for weight loss were 7.64 times more likely.
The paper published in JAMA Ophthalmology on July 3, 2024. By the end of that month it had been read more than the top three JAMA Ophthalmology articles of all of 2023 combined.
A professor named Jakob Grauslund at Odense University Hospital ran the same question on a nationwide database: 424,152 Danes with Type 2 diabetes, followed over five years. Basically every diabetic adult in the country. He found semaglutide users had 2.19 times the NAION risk of patients on other diabetes drugs. And Denmark's annual NAION case count had more than doubled since Ozempic launched there in 2018. From 67.6 cases per year to 148.
A whole country's epidemiology shifting in real time.
A second Danish-Norwegian study followed in June 2025. 44,517 semaglutide users in Denmark, 16,860 in Norway. Same finding. Pooled hazard ratio of 2.81.
The signal replicated. Twice. In countries with no connection to the Harvard clinic, using completely different data, completely different methods.
On June 6, 2025, the European Medicines Agency concluded its formal review.
NAION is a very rare side effect of semaglutide. Up to 1 in 10,000 patients. Official classification. The product information for Ozempic, Wegovy, and Rybelsus across every EU member state had to be updated. By September 30, 2025, every package leaflet carried the warning.
The World Health Organization issued a global medical product alert on June 27.
In November 2025, the Danish government's patient compensation body paid four NAION victims 800,000 kroner. About $123,000. The director said simply: "NAION is a serious condition that causes permanent and incurable damage to vision."
The United States label still does not warn about blindness.
As of May 2026, the FDA says it is "currently evaluating whether there is a safety signal." Eleven months after Europe finished evaluating.
And then, in March 2026, something else surfaced. The FDA sent Novo Nordisk, the company that makes Ozempic, a formal warning letter. Based on an inspection of their New Jersey headquarters, the agency found the company had failed to investigate and timely report serious adverse events tied to semaglutide. Including two patient deaths. And one suicide.
The company's stock fell 3.6 percent. Novo Nordisk said it was confident it could resolve matters to the FDA's satisfaction.
When a pharmaceutical company is not properly reporting patient deaths to the regulator, the regulator's signal detection systems are working with incomplete data. That matters when you are trying to figure out why one agency moved and another has not.
Nobody fully knows why the drug does this to some eyes.
The leading theories involve blood pressure, speed of blood sugar correction, dehydration from gastrointestinal side effects. Some researchers think GLP-1 receptors in ocular tissue may be directly involved. Some think the sympathetic nervous system is implicated somehow. The honest answer is that the mechanism is not settled and European regulators decided the population-level evidence was sufficient to require a warning without needing to know the exact molecular pathway.
That is normal pharmacovigilance practice. You do not need to know how something breaks to tell people it might break.
KFF's November 2025 health poll found 12 percent of American adults are currently on a GLP-1 drug. About 31 million people. Up from 6 percent in May 2024.
Novo Nordisk says it has treated 46 million patients globally with its diabetes and obesity drugs since 2019. The company made the equivalent of roughly $45 billion in 2025. Goldman Sachs projects the global GLP-1 market could reach $100 billion per year by 2030.
One in ten thousand sounds like a small number until you multiply it by 31 million.
That math gives you 3,100 Americans potentially losing vision in one eye per year. At the conservative European estimate. The Harvard odds ratios suggest the real number could be much higher for patients with the anatomical risk factor that most people do not know they have until it is too late.
None of them are being warned.
The ophthalmologists who study this are not telling people to quit the drug. The American Academy of Ophthalmology and the North American Neuro-Ophthalmology Society have both said clearly that patients should not stop semaglutide based on this evidence alone. The cardiovascular benefits for high-risk patients are real. Pulling someone off the drug does not make them neutral. It exposes them to the heart attack the drug was preventing.
What they are saying, quietly, is this: if you are on Ozempic and you notice any sudden change in the vision of one eye, even something small that seems like it might be nothing, stop the drug and get to an ophthalmologist that same day. Not tomorrow. That day.
Because the second eye is the thing worth protecting.
Todd Engel's right eye went on New Year's Eve 2023. He kept taking his Ozempic because nobody told him not to. His left eye went in October 2024.
He filed his lawsuit in April 2025.
He sat through his grandson's bar mitzvah and listened.
He said: "I want the manufacturers of Ozempic to see me."
There are 31 million Americans on these drugs right now.
The label still says nothing about the eyes.
